The price of Sindilizumab is 2843 yuan 100mg/vial. Sindilizumab is China’s independent research and development of the second PD-1 cancer immunotherapy drugs, listed in 2018, January 2021 into the list of medicare drugs, most areas Sindilizumab price of 2843 yuan 100mgm/vial, but the specific still need to look at the local health insurance reimbursement policy to determine, there will be some differences. Sindilizumab can specifically bind to PD-1 molecules on the surface of T-cells, thus blocking the programmed death of PD-1, and at the same time activating the anti-tumor ability of lymphocytes, playing a role in the treatment of tumors, and is mostly used in the treatment of relapsed or refractory classical Hodgkin’s lymphoma, lung cancer, liver cancer and other treatments. Sindilizumab, like other tumor immunotherapy drugs, may cause immune-related adverse reactions, such as white blood cell and platelet decline, as well as immune-related hepatitis, hypothyroidism, etc., and should be used under the guidance of a doctor.